Get the Stockscreener App
138.85
0.29%
0.495
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $138.85, with a volume of 2.18M.
It is up +0.29% in the last 24 hours and up +3.33% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$138.36
Open:
$138.36
24h Volume:
2.18M
Relative Volume:
0.30
Market Cap:
$172.11B
Revenue:
$29.79B
Net Income/Loss:
$9.22B
P/E Ratio:
18.89
EPS:
7.3494
Net Cash Flow:
$10.23B
1W Performance:
+4.28%
1M Performance:
+3.33%
6M Performance:
-10.64%
1Y Performance:
+17.22%
1-Day Range:
$136.63
$139.49
1-Week Range:
$132.01
$139.49
52-Week Range:
$108.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
138.80 | 171.56B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,188.67 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.57 | 627.42B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
250.37 | 440.83B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
135.73 | 335.14B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.03 | 286.78B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Buy |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-11-26 | Reiterated | Needham | Buy |
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
In Win for Gilead, Fourth Circuit Affirms Injunction Blocking Drug Importation Scheme - IPWatchdog.com
Gilead yanks out a thorn in its side in major court ruling - thestreet.com
Simplicity Wealth LLC Invests $1.36 Million in Gilead Sciences, Inc. $GILD - MarketBeat
20,266 Shares in Gilead Sciences, Inc. $GILD Acquired by OneDigital Investment Advisors LLC - MarketBeat
Gilead Sciences stock holds steady as Q2 2026 loss sharpens focus on oncology strategy - AD HOC NEWS
N.E.W. Advisory Services LLC Takes $1.38 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
HBK Sorce Advisory LLC Invests $4.01 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Johnson Wealth Management LLC Makes New $2.41 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Flputnam Investment Management Co. Invests $8.96 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Global Retirement Partners LLC Purchases Shares of 34,604 Gilead Sciences, Inc. $GILD - MarketBeat
442,000 Shares in Gilead Sciences, Inc. $GILD Acquired by Alberta Investment Management Corp - MarketBeat
AMG National Trust Bank Purchases Shares of 26,675 Gilead Sciences, Inc. $GILD - MarketBeat
Balm in Gilead hosts free health forum at local church to educate folks about lung cancer - WDAM-TV
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal - Seeking Alpha
One Wealth Advisors LLC Purchases New Position in Gilead Sciences, Inc. $GILD - MarketBeat
Oppenheimer Asset Management Inc. Buys Shares of 111,624 Gilead Sciences, Inc. $GILD - MarketBeat
Summit Global Investments Buys New Shares in Gilead Sciences, Inc. $GILD - MarketBeat
Centric Wealth Management Takes $3.52 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Cornerstone Capital Inc. Purchases New Position in Gilead Sciences, Inc. $GILD - MarketBeat
ABN AMRO Bank N.V. Purchases Shares of 191,290 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead SciencesGISStock Price & News - The Motley Fool
Abundance Wealth Counselors Grows Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst? - Yahoo Finance
Appeals court backs Gilead in ruling that threatens overseas prescription drug programs - qz.com
Gilead Sciences, Inc. $GILD Shares Bought by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Monument Capital Management Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Confluence Wealth Services Inc. Acquires 7,986 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Position Lifted by Exchange Traded Concepts LLC - MarketBeat
ABN Amro Investment Solutions Has $32.39 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
4th Circ. Won't Undo Block Of Gilead-Branded Drug Imports - Law360
Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine - Yahoo Finance
Gilead Scores Win to Keep Pause on Cheaper, Foreign Drug Imports - Bloomberg Law News
Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run - Yahoo Finance
Thomasville National Bank Purchases New Shares in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead exercises option for MacroGenics pre-clinical bispecific program - The Pharma Letter
Moody Lynn Lieberson & Walker LLC Has $13.33 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Why Gilead Sciences (GILD) Is Back In The Spotlight - Yahoo Finance
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call - Yahoo Finance
Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics - Yahoo Finance
FY2026 EPS Estimates for Gilead Sciences Reduced by Analyst - MarketBeat
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today - Sahm
MacroGenics stock rises on $10M Gilead option exercise By Investing.com - Investing.com South Africa
MacroGenics stock rises on $10M Gilead option exercise - Investing.com
Gilead Sciences (GILD) EVP converts 6,002 RSUs, with 2,908 shares withheld - Stock Titan
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program - The Manila Times
Gilead Sciences options activity points to institutional conviction on 2026 upside - Investing.com
Gilead Sciences Target of Unusually High Options Trading (NASDAQ:GILD) - MarketBeat
FY2027 EPS Estimate for Gilead Sciences Lowered by Analyst - MarketBeat
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.09%
2.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):